Best Clean Energy Stocks To Invest In 2018


After positive mid-stage trial data suggested earlier this year that it might be able to reshape the treatment of kidney failure in lupus patients, Aurinia Pharmaceuticals (NASDAQ:AUPH)has announced plans for a late-stage study that could eventually allow it to win regulatory OKs in the U.S., Europe, and Japan.

What’s going on

Aurinia Pharmaceuticals is working on voclosporin, a drug that could eventually be used alongside CellCept as standard of care in patients diagnosed with lupus nephritis (LN).


IMAGE SOURCE: GETTY IMAGES.

Over 500,000 people in the U.S. have systemic lupus erythematosus (SLE), and up to 60% of them develop LN, or inflammation of the kidneys that can lead to end-stage kidney disease.Typically, LN patients are prescribed steroids and CellCept in an attempt to control their disease, but steroids can produce unwanted side effects, and CellCept delivers spotty efficacy.

Best Clean Energy Stocks To Invest In 2018: Vuzix Corporation(VUZI)

Advisors’ Opinion:

  • [By James E. Brumley]

    While the economy’s natural — and recurring — cycles favor different kinds of stocks at different times, not every great trend is necessarily a cyclical one. Sometimes, a trend is rooted in a technological development that changes cultural norms. The advent of the smartphone, for example, has made constant connectivity to the world around part of how we live our daily lives.

    These mega-trends present tremendous opportunities for investors too, provided they’re savvy enough to see them coming and play them the right way.

    One such mega-trend newly underway right now is the proliferation of wearables… devices that meld clothing (often a wrist-worn device) and technology to perform a function that couldn’t be performed otherwise. Much of the same technology that made the smartphone possible are now ushering in wearables.


    It’s not been a smooth beginning. however.

    While the buzz was strong and expectations reached a peak two years ago when Fitbit Inc (NYSE:FIT) was all the rage and in the wake of its IPO, the company’s growth wasn’t to be sustained. The company is struggling to muster any growth now, and FIT shares have fallen to a tenth of their value seen in late-2015, when the euphoria was strongest.

    Fitbit’s slowdown has been mirrored by other companies in the space. The wearables market only grew 3.1% in Q3 of 2016.

    On the flipside, while the debacle of Fitbit — the wearable industry’s iconic company — has been a painful, it’s also been a learning experience. And, it’s not as if the slowdown is unfurling without the wearables market never reaching a respectable size. International Data Corporation estimates were 23 million ‘wearables’ delivered in the third quarter of last year alone.


    Moreover, the fizzling of the market hasn’t turned into a reason to swear off wearables as an investment opportunity… quite the opposite, actually. It’s just now become considerably clearer what consumers want an

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
  • [By William Patalon III]

    Vuzix Corp. (Nasdaq: VUZI) – the “augmented reality” company whose shares more than doubled following our September 2015 recommendation – said that its new “smart glasses” were just honored with a “Wearable Device of the Year” award.

Best Clean Energy Stocks To Invest In 2018: Oxbridge Re Holdings Limited(OXBR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Oxbridge Re Holdings Ltd. (NASDAQ: OXBR) were down 18 percent to $2.72. Oxbridge Re Holdings reported a Q3 loss of $3.97 per share on sales of $19.33 million.

Best Clean Energy Stocks To Invest In 2018: Bioanalytical Systems, Inc.(BASI)


Advisors’ Opinion:

  • [By Lisa Levin] Related SOFO 12 Biggest Mid-Day Losers For Tuesday Earnings Scheduled For December 10, 2015
    Related WSCI 15 Biggest Mid-Day Losers For Wednesday Earnings Scheduled For June 21, 2016 Companies Reporting Before The Bell
    Rite Aid Corporation (NYSE: RAD) is projected to report its quarterly earnings at $0.04 per share on revenue of $8.23 billion.
    Conagra Brands Inc (NYSE: CAG) is estimated to report its quarterly earnings at $0.45 per share on revenue of $2.11 billion.
    Bioanalytical Systems, Inc. (NASDAQ: BASI) is expected to report earnings for the fourth quarter.


     

  • [By Alex McGuire]

    Here’s a list of the top 10 penny stocks to watch in March, which includes the biggest gainers last month…

    Penny StockCurrent Stock PriceFebruary 2017 ReturnZosano Pharma Corp. (Nasdaq: ZSAN)$2.56+123.3%Bellerophon Therapeutics Inc. (Nasdaq: BLPH)$1.25+113.8%Peregrine Pharmaceuticals (Nasdaq: PPHM)$0.59+101.7%Galectin Therapeutics Inc. (Nasdaq: GALT)$1.79+91.9%Bioanalytical Systems Inc. (Nasdaq: BASI)$1.58+90.6%CymaBay Therapeutics Inc. (Nasdaq: CBAY)$3.50+89.8%Vermillion Inc. (Nasdaq: VRML)$2.56+86.3%Naked Brand Group Inc.(Nasdaq:NAKD)$2.16+76%Eyegate Pharmaceuticals Inc. (Nasdaq: EYEG)$2.63+73.9%Benitec Biopharma Ltd. (Nasdaq ADR: BNTC)$2.60+59.9%


    The best-performing penny stock – Zosano Pharma Corp. – soared an incredible 123.3% from Feb. 1 to Feb. 28. To put those gains into perspective, that’s more than five times the S&P 500’s 23% climb in the last 12 months.

Best Clean Energy Stocks To Invest In 2018: Berkshire Hathaway Inc.(BRK.A)

Advisors’ Opinion:

  • [By Sarfaraz Khan]

    Shares of Warren Buffett-ledBerkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B)delivered a blowout performance in 2016 by easily beating the S&P 500 (INDX:SPAL) and Dow Jones Industrial Average (INDX:INDU) and ending the year with a market cap of almost $400 billion for the first time in its history. And I believe the good times will continue in 2017.

  • [By Jack Delaney]

    Berkshire Hathaway Inc. (NYSE: BRK.A) doesn’t pay a dividend, but the company and the stock both benefit greatly from owning shares of some of the best dividend aristocrats on the market.

  • [By Yasin Ebrahim]
     

    Berkshire Hathaway Inc. (NYSE:BRK.A) is an American conglomerate with investments in a variety of businesses from American Express to Coca-Cola. It reported Q3 earnings last week, which were in line with analysts’ expectations, as the group revealed a 7% increase in operating profit compared to the same period last year.

  • [By Ashley Moore]

    At $257,200.00 a share, investing in Berkshire Hathaway Inc. (NYSE: BRK.A) is simply not an option for most retail investors like us. But the nearly 50 other “Warren Buffett stocks” that Berkshire invests in come at a much lower price point.

  • [By Yasin Ebrahim]

    Berkshire Hathaway Inc. (NYSE:BRK.A) is an American conglomerate with investments in a variety of businesses from American Express to Coca-Cola. It reported Q3 earnings last week, which were in line with analysts expectations, as the group revealed a 7% increase in operating profit compared to the same period last year.

Best Clean Energy Stocks To Invest In 2018: Spark Therapeutics, Inc.(ONCE)


Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Spark Therapeutics Inc (NASDAQ: ONCE) were down 36 percent to $47.08 on preliminary SPK-8011 trial data.

    Athenex Inc (NASDAQ: ATNX) was down, falling around 13 percent to $13.95. Almirall and Athenex reported a strategic partnership to develop and commercialize KX2-391 in the U.S. and Europe.

  • [By Chris Lange]

    Spark Therapeutics Inc. (NASDAQ: ONCE) saw its shares take a big step back on Monday after the firm reported less than favorable results at the American Society of Hematology (ASH) annual meeting. Analysts have taken this opportunity to weigh in on the stock:

  • [By Jim Robertson]

    On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Spark Therapeutics (NASDAQ: ONCE):

    Financially, Spark Therapeutics has over $300M in cash on the books and no debt to speak of yet, which equates to a share price of just over four times cash. The Company has generated over $20M in revenue for the trailing twelve months, and although the Company is expected to continue to lose money for the next few years, any strong clinical data that hits the tape could rocket shares of ONCE overnight, just like we’ve seen with so many others over the years.

  • [By Paul Ausick]

    Spark Therapeutics Inc. (NASDAQ: ONCE) dropped 44% Monday to post a new 52-week low of $41.06 after closing at $73.38 on Friday. The 52-week high is $91.75. Volume was around 13.5 million, nearly 30 times the daily average of about 480,000. The company’s hemophilia A drug posted disappointing trial results.

Leave a Reply

Your email address will not be published. Required fields are marked *